Clear, sourced knowledge about peptides.Peptides, with sources

See all sourcesSources

Search peptides, guides and rules

Melanotan II

Early studies in humans

Skin, ageing and wellbeing
Written by The Peptideguiden editors. Sources checked 25 October 2026. Last updated 29 October 2026.

A freckled woman in evening sun by the sea
Research areaSkin colour and sun
Contents
  1. In short
  2. What is Melanotan II?
  3. What does the research say about Melanotan II?
  4. Questions and answers
  5. Norwegian vendor feedback
  6. Sources (10)

In short

  • Melanotan II is a synthetic version of a hormone that darkens the skin.
  • Small studies from the 1990s showed that it gives darker skin. It also gave erections.
  • A related substance, afamelanotide, is approved in the EU for a rare light sensitivity, and the related bremelanotide has been tested in large studies.
  • A new study is testing melanotan II together with light therapy for vitiligo.

Fact box

Type
Research compound
Research
Early human studies
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Other names
melanotan 2, MT-II, MT2

What is Melanotan II?

Melanotan II is a lab-made peptide that mimics alpha-MSH, a hormone that makes the skin produce more pigment. It is often called the tanning injection because it gives darker skin.

The body makes the hormone alpha-MSH, which among other things controls how much pigment the skin produces. Melanotan II is a synthetic and more potent version of part of this hormone.[1]

It acts on more than the skin. It also affects other receptors in the body, and in the studies the men had erections as a side effect.[1][2] This led to research on related substances for sexual health.

Melanotan II should not be confused with afamelanotide, a related substance approved in the EU for a rare inherited condition where the skin tolerates very little light.[3][4]

A new study with 60 participants will test melanotan II together with light therapy for vitiligo. It started in 2026, and there are no results yet.[5]

The amino acid sequence in the fact box comes from PubChem.[6]

What does the research say about Melanotan II?

Small studies in humans, most of them from the 1990s, show that melanotan II gives darker skin and erections. Related substances have since been developed into approved medicines.

What does the research say about Melanotan II?
UseStudiesResearch
Darker skin1 study · Pilot study · n = 3Early human studies
Erection problems2 studies · RCT · n = 20Early human studies

RCT means randomised controlled trial. How to read a study

Darker skin

In a small pilot study from 1996, three healthy men received melanotan II and salt water on alternate days for two weeks. Two of them got darker skin on the face and upper body.[1]

Erection problems

Two small placebo-controlled studies with ten men each tested melanotan II for erection problems. In the first, eight of ten men had an erection.[2] The second study also found an effect.[7]

The related substance bremelanotide has since been tested in two large studies in women with low sexual desire.[8]

Questions and answers about Melanotan II

Does melanotan give a tan?

Yes. In the small studies, melanotan II gave darker skin on the face and upper body.

Is melanotan the same as afamelanotide?

No. Afamelanotide is a related substance approved in the EU for a rare inherited light sensitivity. Melanotan II is a different substance.

What people say about Norwegian vendors

Read a detailed comparison

Explore feedback on ordering, delivery and customer support from Norwegian peptide vendors. For education only, with no promotion or recommendations.

Sources

  1. [1]

    Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996.

    PMID 8637402DOIPilot study · n = 3

  2. [2]

    Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998.

    PMID 9679884RCT · n = 10

  3. [3]

    Scenesse (afamelanotide): EPAR. Authorised in the EU on 22.12.2014. European Medicines Agency (EMA). 2014.

    European Medicines Agency (EMA)Official source

  4. [4]

    Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015.

    PMID 26132941DOIRCT

  5. [5]

    Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (NCT07437560). ClinicalTrials.gov. 2026.

    ClinicalTrials.govRCT · n = 60

  6. [6]

    Melanotan II (CID 92432). PubChem, National Library of Medicine. 2026.

    PubChem, National Library of MedicineOther

  7. [7]

    Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000.

    PMID 11018622DOIRCT · n = 10

  8. [8]

    Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019.

    PMID 31599840DOIRCT · n = 1,267

  9. [9]

    The 2026 Prohibited List. International Standard. World Anti-Doping Agency (WADA). 2026.

    World Anti-Doping Agency (WADA)Official source

  10. [10]

    Seks peptider på dopinglisten av hensyn til folkehelsen. Direktoratet for medisinske produkter (DMP). 2026.

    Direktoratet for medisinske produkter (DMP)Official source

Change log

  • 2026-10-29 English version published, written from the Norwegian page. All sources are checked against PubMed, DOI or the source website.